Vor Biopharma Inc. (VOR): Cash & Equivalents
$396.49M
As of 2025-12-31
$107.86M
As of 2026-06-30
+90.1%
3-year compound annual growth
+52.2%
5-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $396.49M | +383.8% | 2026-03-30, Balance as of period end |
| 2024-12-31 | $81.95M | +161.3% | 2026-03-30, Balance as of period end |
| 2023-12-31 | $31.36M | -45.7% | 2025-03-20, Balance as of period end |
| 2022-12-31 | $57.71M | -51.8% | 2024-03-20, Balance as of period end |
| 2021-12-31 | $119.80M | +146.8% | 2023-03-23, Balance as of period end |
| 2020-12-31 | $48.54M | n/a | 2022-03-14, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Vor Biopharma Inc. (VOR) | 2025-12-31 | $396.49M | +383.8% |
| REGENXBIO Inc. (RGNX) | 2025-12-31 | $34.47M | -40.1% |
| Monte Rosa Therapeutics, Inc. (GLUE) | 2025-12-31 | $129.88M | -42.1% |
| Cullinan Therapeutics, Inc. (CGEM) | 2025-12-31 | $88.33M | +6.4% |
| Vericel Corp (VCEL) | 2025-12-31 | $100.09M | +34.3% |
| ImmunityBio, Inc. (IBRX) | 2025-12-31 | $88.33M | -38.4% |
| Adaptive Biotechnologies Corp (ADPT) | 2025-12-31 | $70.50M | +47.1% |
| BioCryst Pharmaceuticals Inc (BCRX) | 2025-12-31 | $89.74M | -14.3% |
| Sana Biotechnology, Inc. (SANA) | 2025-12-31 | $71.87M | -43.7% |
Compare VOR, RGNX, GLUE, CGEM side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗